Abstract
Introduction The BCL2 inhibitor venetoclax is an emerging standard of care in the treatment of CLL.1,2 Although highly effective in achieving control of CLL, including clearance of minimal residual disease,3 most patients develop resistance following prolonged exposure to venetoclax.4 We review current knowledge regarding the molecular basis behind venetoclax resistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
